DOCSLIB.ORG

The Syndromes of Thrombotic Microangiopathy: a Critical Appraisal on Complement Dysregulation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Syndromes of Thrombotic Microangiopathy: a Critical Appraisal on Complement Dysregulation Journal of Clinical Medicine Review The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation Sjoerd A. M. E. G. Timmermans 1,2,* and Pieter van Paassen 1,2 1 Department Nephrology and Clinical Immunology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands; [email protected] 2 Department Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), 6229 HX Maastricht, The Netherlands * Correspondence: [email protected] Abstract: Thrombotic microangiopathy (TMA) is a rare and potentially life-threatening condition that can be caused by a heterogeneous group of diseases, often affecting the brain and kidneys. TMAs should be classified according to etiology to indicate targets for treatment. Complement dysregulation is an important cause of TMA that defines cases not related to coexisting conditions, that is, primary atypical hemolytic uremic syndrome (HUS). Ever since the approval of therapeutic complement inhibition, the approach of TMA has focused on the recognition of primary atypical HUS. Recent advances, however, demonstrated the pivotal role of complement dysregulation in specific subtypes of patients considered to have secondary atypical HUS. This is particularly the case in patients presenting with coexisting hypertensive emergency, pregnancy, and kidney transplantation, shifting the paradigm of disease. In contrast, complement dysregulation is uncommon in patients with other coexisting conditions, such as bacterial infection, drug use, cancer, and autoimmunity, among Citation: Timmermans, S.A.M.E.G.; other disorders. In this review, we performed a critical appraisal on complement dysregulation and van Paassen, P. The Syndromes of the use of therapeutic complement inhibition in TMAs associated with coexisting conditions and Thrombotic Microangiopathy: A outline a pragmatic approach to diagnosis and treatment. For future studies, we advocate the term Critical Appraisal on Complement complement-mediated TMA as opposed to the traditional atypical HUS-type classification. Dysregulation. J. Clin. Med. 2021, 10, 3034. https://doi.org/10.3390/ Keywords: thrombotic microangiopathy; atypical hemolytic uremic syndrome; complement; jcm10143034 hypertensive emergency; pregnancy; kidney transplantation; eculizumab Academic Editor: Lee Ann MacMillan-Crow 1. Integrated Discussion Received: 28 May 2021 Thrombotic microangiopathy (TMA) is a rare, potentially life-threatening condition Accepted: 6 July 2021 Published: 8 July 2021 that reflects tissue responses to severe endothelial damage caused by distinct disorders, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (HUS). Publisher’s Note: MDPI stays neutral Despite heterogeneity, TMAs typically manifest with consumptive thrombocytopenia, with regard to jurisdictional claims in microangiopathic hemolytic anemia, and ischemic organ damage, often affecting the brain published maps and institutional affil- and kidneys. TMAs should be classified according to etiology to indicate targets for iations. treatment (Figure1)[ 1,2]. For example, thrombotic thrombocytopenic purpura is caused by a severe deficiency of von Willebrand cleaving protease (also known as a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13)) [3], and thus treatment should restore ADAMTS13’s function. The term HUS, either atypical or not, has been used to define any TMA with a normal functional activity of ADAMTS13. Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. HUS occurring on the background of complement dysregulation defines primary atyp- This article is an open access article ical HUS, indicating a diagnosis of exclusion [1]. Many of such patients present with rare distributed under the terms and variants in complement genes and/or autoantibodies that inhibit complement regulatory conditions of the Creative Commons proteins [4,5]. Primary atypical HUS is considered an orphan disease, with an incidence of Attribution (CC BY) license (https:// <1 per million population per year [6]. Most patients with HUS (i.e., ~90%) present with creativecommons.org/licenses/by/ coexisting conditions, assumed to be the etiologic factor of disease, and have been termed 4.0/). secondary atypical HUS (Figure1)[ 7]. Known coexisting conditions linked to secondary J. Clin. Med. 2021, 10, 3034. https://doi.org/10.3390/jcm10143034 https://www.mdpi.com/journal/jcm J. Clin. Med. 2021, 10, x FOR PEER REVIEW 2 of 19 present with coexisting conditions, assumed to be the etiologic factor of disease, and have been termed secondary atypical HUS (Figure 1) [7]. Known coexisting conditions linked to secondary atypical HUS are hypertensive emergency, pregnancy, kidney transplanta- tion, bacterial infections, drug use, cancer, autoimmunity, and hematologic stem cell transplantation (HSCT), among others. Recent advances, however, linked complement dysregulation to specific subtypes of so-called secondary atypical HUS and poor kidney J. Clin. Med. 2021, 10, 3034 outcomes [8–10]. Thus, the traditional atypical HUS-type classification2 ofis 19not absolute be- cause complement dysregulation can be present along the spectrum of HUS [11]. In the era of therapeutic complement inhibition [12–14], the challenge is to recognize patients atypical HUS are hypertensive emergency, pregnancy, kidney transplantation, bacterial withinfections, complement drug use, dysregulation cancer, autoimmunity, in the and earliest hematologic possible stem stage cell to transplantation prevent end-stage kidney disease(HSCT), among(ESKD). others. Recent advances, however, linked complement dysregulation to specificIn subtypesthis review, of so-called we performed secondary atypical a critical HUS appraisal and poor kidneyon complement outcomes [8 –dysregulation10]. and therapeuticThus, the traditional complement atypical HUS-typeinhibition classification in HUS pres is notenting absolute with because coexisting complement conditions and out- dysregulation can be present along the spectrum of HUS [11]. In the era of therapeutic line a pragmatic approach to diagnosis and treatment. We advocate to use the term com- complement inhibition [12–14], the challenge is to recognize patients with complement plement-mediateddysregulation in the earliest (C-)TMA possible to stagedefine to preventcases related end-stage to kidneycomplement disease (ESKD). dysregulation. Figure 1. 1.The The atypical atypical HUS-type HUS-type classification classification [1,2]. [1,2]. In this review, we performed a critical appraisal on complement dysregulation and therapeuticSecondary complement atypical inhibition HUS represents in HUS presenting the majority with coexisting of TMAs, conditions that is, ~ and90%; Shiga toxin- producingoutline a pragmatic E. coli (STEC)-HUS, approach to diagnosis thrombotic and treatment. thrombocytop We advocateenic purpura to use the (TTP), term and primary atypicalcomplement-mediated HUS are responsible (C-)TMA to definefor 6%, cases 3%, related and to3% complement of TMAs dysregulation.[7]. DGKE, diacylglycerol ki- Secondary atypical HUS represents the majority of TMAs, that is, ~90%; Shiga toxin- naseproducing epsilon.E. coli HSCT,(STEC)-HUS, hematopoietic thrombotic thrombocytopenicstem cell transplantation. purpura (TTP), and primary atypical HUS are responsible for 6%, 3%, and 3% of TMAs [7]. DGKE, diacylglycerol kinase 2.epsilon. Primary HSCT, Atypical hematopoietic HUS, stem a Prototypic cell transplantation. C-TMA 2. PrimaryThe complement Atypical HUS, system a Prototypic is an C-TMA ancient and conserved effector system involved in the defenseThe complementagainst pathogens system is anand ancient host and homeostasi conserveds, effector which system can involvedbe activated in the via the classic, lectin,defense and against alternative pathogens pathways and host homeostasis, (Figure 2A). which The can alternative be activated pathway via the classic, is continuously ac- tivelectin, through and alternative a mechanism pathways (Figure known2A). as The the alternative thick-over, pathway i.e., is continuouslyspontaneou actives hydrolysis of C3. Hostthrough cells, a mechanism including known the endothelium, as the thick-over, are i.e., pr spontaneousotected from hydrolysis the harmful of C3. Host effects of comple- cells, including the endothelium, are protected from the harmful effects of complement mentactivation activation by regulatory by regulatory proteins. proteins. InIn the the late late 1980s, 1980s, complement complement dysregulation dysregulation (i.e., factor (i.e., H factor deficiency) H deficiency) was found was found in twoin two brothers brothers with with (primary(primary atypical) atypical) HUS HUS [15]. [15]. Thereafter, Thereafter, a linkage a linkage study in study three in three fami- liesfamilies identified identified a variant a variant in in CFHCFH [16][16] locatedlocated in in the the C’-terminal-reduced C’-terminal-reduced factor factor H’s H’s binding binding to the endothelium [17]. At present, >600 variants in complement genes have to the endothelium [17]. At present, >600 variants in complement genes have been identi- been identified in primary atypical HUS [18], with a prevalence of >50% [4,5]. Rare fiedvariants in primary (i.e., minor atypical allele frequency HUS [18], of with <0.1%) a [prevalence19] in CFH, CFIof >50%, CD46 [4,5]., C3, andRareCFB variants (i.e., mi- norare ofallele particular frequency interest of [ 18<0.1%)]. CFH [19], CFI in, andCFHCD46, CFI,variants
Load more

Recommended publications
  • A Cross Sectional Study of Cutaneous Manifestations in 300 Patients of Diabetes Mellitus
    International Journal of Advances in Medicine Khuraiya S et al. Int J Adv Med. 2019 Feb;6(1):150-154 http://www.ijmedicine.com pISSN 2349-3925 | eISSN 2349-3933 DOI: http://dx.doi.org/10.18203/2349-3933.ijam20190122 Original Research Article A cross sectional study of cutaneous manifestations in 300 patients of diabetes mellitus Sandeep Khuraiya1*, Nancy Lal2, Naseerudin3, Vinod Jain3, Dilip Kachhawa3 1Department of Dermatology, 2Department of Radiation Oncology , Gandhi Medical College, Bhopal, Madhya Pradesh, India 3Department of Dermatology, Dr. SNMC, Jodhpur, Rajasthan, India Received: 13 December 2018 Accepted: 05 January 2019 *Correspondence: Dr. Sandeep Khuraiya, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Diabetes Mellitus (DM) is a worldwide problem and one of the most common endocrine disorder. The skin is affected by both the acute metabolic derangements and the chronic degenerative complications of diabetes. Methods: The present study was a one-year cross sectional study from January 2014 to December 2014. All confirmed cases of DM with cutaneous manifestations irrespective of age, sex, duration of illness and associated diseases, willing to participate in the study were included in the study. Routine haematological and urine investigations, FBS, RBS and HbA1c levels were carried out in all patients. Results: A total of 300 patients of diabetes mellitus with cutaneous manifestations were studied.
    [Show full text]
  • Note for Guidance on Clinical Investigation of Medicinal Products for the Treatment of Peripheral Arterial Occlusive Disease
    The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 April 2002 CPMP/EWP/714/98 rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE DISCUSSION IN THE EFFICACY WORKING PARTY September 1999 – September 2000 TRANSMISSION TO CPMP November 2000 RELEASE FOR CONSULTATION November 2000 DEADLINE FOR COMMENTS May 2001 DISCUSSION IN THE EFFICACY WORKING PARTY November 2001 – February 2002 TRANSMISSION TO CPMP April 2002 ADOPTION BY CPMP April 2002 DATE FOR COMING INTO OPERATION October 2002 Note: This revised Note for guidance will replace the previous Note for guidance (CPMP/EWP/233/95) , adopted in November 1995. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 8613 E-mail: [email protected] http://www.emea.eu.int EMEA 2002 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged NOTE FOR GUIDANCE ON CLINICAL INVESTIGATIONS OF MEDICINAL PRODUCTS IN THE TREATMENT OF CHRONIC PERIPHERAL ARTERIAL OCCLUSIVE DISEASE TABLE OF CONTENTS 1. INTRODUCTION .................................................................................................... 4 2. GENERAL CONSIDERATIONS REGARDING PAOD TRIALS..................... 4 2.1 PAOD Classification and Epidemiological Background ...................................... 4 2.2 Clinical Trial Features ............................................................................................
    [Show full text]
  • IWGDF Guideline on Diagnosis, Prognosis and Management of Peripheral Artery Disease in Patients with a Foot Ulcer and Diabetes
    IWGDF Guideline on diagnosis, prognosis and management of peripheral artery disease in patients with a foot ulcer and diabetes Part of the 2019 IWGDF Guidelines on the Prevention and Management of Diabetic Foot Disease IWGDF Guidelines AUTHORS Robert J. Hinchlife1, Rachael O. Forsythe2, Jan Apelqvist3, Ed J. Boyko4, Robert Fitridge5, Joon Pio Hong6, Konstantinos Katsanos7, Joseph L. Mills8, Sigrid Nikol9, Jim Reekers10, Maarit Venermo11, R. Eugene Zierler12, Nicolaas C. Schaper13 on behalf of the International Working Group on the Diabetic Foot (IWGDF) INSTITUTIONS 1 Bristol Centre for Surgical Research, University of Bristol, Bristol, UK 2 British Heart Foundation / University of Edinburgh Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, UK 3 Department of Endocrinology, University Hospital of Malmö, Sweden 4 Seattle Epidemiologic Research and Information Centre-Department of Veterans Afairs Puget Sound Health Care System and the University of Washington, Seattle, Washington, USA 5 Vascular Surgery, The University of Adelaide, Adelaide, South Australia, Australia 6 Asan Medical Center University of Ulsan, Seoul, Korea 7 Patras University Hospital School of Medicine, Rion, Patras, Greece 8 SALSA (Southern Arizona Limb Salvage Alliance), University of Arizona Health Sciences Center, Tucson, Arizona, USA 9 Asklepios Klinik St. Georg, Hamburg, Germany 10 Department of Vascular Radiology, Amsterdam Medical Centre, The Netherlands 11 Helsinki University Hospital, University of Helsinki, Finland 12 Department of Surgery, University of Washington, Seattle, Washington, USA 13 Div. Endocrinology, MUMC+, CARIM and CAPHRI Institute, Maastricht, The Netherlands KEYWORDS diabetic foot; foot ulcer; guidelines; peripheral artery disease; surgery; diagnosis; prognosis; vascular disease www.iwgdfguidelines.org IWGDF PAD Guideline ABSTRACT The International Working Group on the Diabetic Foot (IWGDF) has published evidence-based guidelines on the prevention and management of diabetic foot disease since 1999.
    [Show full text]
  • Coronary Microvascular Dysfunction
    Journal of Clinical Medicine Review Coronary Microvascular Dysfunction Federico Vancheri 1,*, Giovanni Longo 2, Sergio Vancheri 3 and Michael Henein 4,5,6 1 Department of Internal Medicine, S.Elia Hospital, 93100 Caltanissetta, Italy 2 Cardiovascular and Interventional Department, S.Elia Hospital, 93100 Caltanissetta, Italy; [email protected] 3 Radiology Department, I.R.C.C.S. Policlinico San Matteo, 27100 Pavia, Italy; [email protected] 4 Institute of Public Health and Clinical Medicine, Umea University, SE-90187 Umea, Sweden; [email protected] 5 Department of Fluid Mechanics, Brunel University, Middlesex, London UB8 3PH, UK 6 Molecular and Nuclear Research Institute, St George’s University, London SW17 0RE, UK * Correspondence: [email protected] Received: 10 August 2020; Accepted: 2 September 2020; Published: 6 September 2020 Abstract: Many patients with chest pain undergoing coronary angiography do not show significant obstructive coronary lesions. A substantial proportion of these patients have abnormalities in the function and structure of coronary microcirculation due to endothelial and smooth muscle cell dysfunction. The coronary microcirculation has a fundamental role in the regulation of coronary blood flow in response to cardiac oxygen requirements. Impairment of this mechanism, defined as coronary microvascular dysfunction (CMD), carries an increased risk of adverse cardiovascular clinical outcomes. Coronary endothelial dysfunction accounts for approximately two-thirds of clinical conditions presenting with symptoms and signs of myocardial ischemia without obstructive coronary disease, termed “ischemia with non-obstructive coronary artery disease” (INOCA) and for a small proportion of “myocardial infarction with non-obstructive coronary artery disease” (MINOCA). More frequently, the clinical presentation of INOCA is microvascular angina due to CMD, while some patients present vasospastic angina due to epicardial spasm, and mixed epicardial and microvascular forms.
    [Show full text]
  • Origin of the Microangiopathic Changes in Diabetes
    ORIGIN OF THE MICROANGIOPATHIC CHANGES IN DIABETES A. H. BARNETT Birmingham SUMMARY its glycosidally linked disaccharide units. Such alterations The mechanism of development of microangiopathy is lead to abnormal packing of the peptide chains producing incompletely understood, but relates to a number of excessive leakiness of the membrane. The exact mech­ ultrastructural, biochemical and haemostatic processes. anisms of thickening and leakiness of basement mem­ These include capillary basement membrane thickening, brane and their relevance to diabetic complications are not non-enzymatic glycosylation, possibly increased free rad­ entirely clear, but appear to involve several biochemical ical activity, increased flux through the polyol pathway mechanisms. and haemostatic abnormalities. The central feature Non-enzymatic Glycosylation appears to be hyperglycaemia, which is causally related to the above processes and culminates in tissue ischaemia. In the presence of persistent hyperglycaemia glucose This article will briefly describe these processes and will chemically attaches to proteins non-enzymatically to form discuss possible pathogenic interactions which may lead a stable product (keto amine or Amadori product) of which to the development of the pathological lesion. glycosylated haemoglobin is the best-known example. In long-lived tissue proteins such as collagen the ketoamine Microangiopathy is a specific disorder of the small blood then undergoes a series of reactions resulting in the vessels which causes much morbidity and mortality in dia­ development of advanced glycosylation end products betic patients. Diabetic retinopathy is the commonest (AGE) (Fig. 1).5 AGE are resistant to degradation and con­ cause of blindness in the working population of the United tinue to accumulate indefinitely on long-lived proteins.
    [Show full text]
  • A Case of Malignant Hypertension-Induced Thrombotic Microangiopathy with Gradually Improved Renal Function Using Appropriate Antihypertensives
    10.5152/turkjnephrol.2021.4404 Case Report A Case of Malignant Hypertension-Induced Thrombotic Microangiopathy with Gradually Improved Renal Function Using Appropriate Antihypertensives Feyza Bora1 , Fatih Yılmaz2 , Hasan Sözel3 , Bahar Akkaya4 1Department of Nephrology, Akdeniz University School of Medicine, Antalya, Turkey 2Department of Nephrology, Antalya Atatürk State Hospital, Antalya, Turkey 3Department of Internal Medicine, Akdeniz University Hospital, Antalya, Turkey 84 4Department of Pathology, Akdeniz University Hospital, Antalya, Turkey Abstract Malignant hypertension sometimes causes microangiopathic hemolytic anemia (MAHA) and thrombotic microangiopathy (TMA). TMA results in the obstruction of arterioles and capillaries due to microvascular thrombosis. The pathological di- agnosis of TMA is done by tissue biopsy. In this process, malignant hypertension-induced TMA must be distinguished from thrombotic thrombocytopenic purpura (TTP) and hemolitic uremic syndrome (HUS). We describe the case of a 45-year-old man with malignant hypertension, MAHA, and severe renal failure. Plasmapheresis was performed until the ADAMTS -13 activity was reported as normal. The patient’s blood pressure was reduced in a controlled manner first using antihyperten- sives, and TMA was confirmed by a kidney biopsy. Based on the normal ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity, other possible conditions that might cause TMA were eliminated, and malign hypertension-induced TMA was diagnosed. After two years, the glomerular filtration rate was found to have increased from 22 to 59.5 ml/min. In cases of severe hypertension associated with TMA, it may sometimes not be easy to establish whether TMA is caused by malignant hypertension or other associated diseases. The treatment of hyperten- sion-induced TMA aims to control hypertension, which leads to the resolution of TMA over time.
    [Show full text]
  • Cutaneous Collagenous Vasculopathy: Papular Form
    Volume 25 Number 8| August 2019| Dermatology Online Journal || Photo Vignette 25(8):8 Cutaneous collagenous vasculopathy: papular form Alberto Conde-Ferreirós1, Mónica Roncero-Riesco1, Javier Cañueto1, Concepción Román-Curto1, Ángel Santos-Briz2 Affiliations: 1Department of Dermatology, University Hospital of Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain, 2Department of Pathology, University Hospital of Salamanca, Paseo de San Vicente, 58-182, 37007, Salamanca, Spain Corresponding Author: Dr. Alberto Conde Ferreirós, University Hospital of Salamanca, Department of Dermatology, Paseo San Vicente, 58-182, 37007, Salamanca (Spain), Email: [email protected] [email protected], Tel: 34-923-29100/34-691-010273 Introduction Abstract Cutaneous collagenous vasculopathy is a rare Cutaneous collagenous vasculopathy is a rare clinicopathological entity; it was first described in clinicopathological entity, first described in 2000. 2000 by Salama and Rosenthal [1]. Cutaneous Cutaneous collagenous vasculopathy has been considered a form of microangiopathy of superficial collagenous vasculopathy has been considered a dermal vessels and produce lesions that appear as form of microangiopathy, which affects superficial telangiectasia. We present a patient with cutaneous vessels. It is characterized by the deposit histopathologic features of cutaneous collagenous of a homogeneous eosinophilic hyaline material in vasculopathy and scattered erythematous papules vascular walls. To date, all cases clinically consist in on the trunk with a striking dermatoscopic finding. progressive asymptomatic cutaneous We propose the term of “cutaneous papular telangiectasias. collagenous vasculopathy” as a new clinical manifestation of this disease. Case Synopsis Keywords: cutaneous collagenous vasculopathy, collagen We report a 68-year-old man with a history of IV, microangiopathy, cutaneous telangiectasias hyperuricemia, hypertension, atrial fibrillation, gout, A B A B Figure 1.
    [Show full text]
  • Hypertensive Emergencies: an Update Paul E
    Hypertensive emergencies: an update Paul E. Marika and Racquel Riverab aDepartment of Medicine, Eastern Virginia Medical Purpose of review School and bDepartment of Pharmacy, Sentara Norfolk General Hospital, Norfolk, Virginia, USA Systemic hypertension (HTN) is a common medical condition affecting over 1 billion people worldwide. One to two percent of patients with HTN develop acute elevations of Correspondence to Paul E. Marik, MD, FCCP, FCCM, Eastern Virginia Medical School, 825 Fairfax Avenue, blood pressure (hypertensive crises) that require medical treatment. However, only Suite 410, Norfolk, VA 23507, USA patients with true hypertensive emergencies require the immediate and controlled E-mail: [email protected] reduction of blood pressure with an intravenous antihypertensive agent. Current Opinion in Critical Care 2011, Recent findings 17:569–580 Although the mortality from hypertensive emergencies has decreased, the prevalence and demographics of this disorder have not changed over the last 4 decades. Clinical experience and reported data suggest that patients with hypertensive urgencies are frequently inappropriately treated with intravenous antihypertensive agents, whereas patients with true hypertensive emergencies are overtreated with significant complications. Summary Despite published guidelines, most patients with hypertensive crises are poorly managed with potentially severe outcomes. Keywords aortic dissection, clevidipine, eclampsia, esmolol, hypertension, hypertensive emergencies, labetalol, nicardipine, pulmonary edema Curr Opin Crit Care 17:569–580 ß 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins 1070-5295 of hypertension (compared to the previous four stages in Introduction JNC VI). In addition, a new category called prehyper- Systemic hypertension (HTN) is a common medical tension was added. Hypertension is defined as a SBP condition affecting over 1 billion people worldwide greater than 140 mmHg or a DBP greater than 90 mmHg and more than 65 million Americans [1,2].
    [Show full text]
  • University of Chicago, November 2004
    CHICAGO DERMATOLOGICAL SOCIETY University of Chicago Section of Dermatology Chicago, Illinois November 17, 2004 TABLE OF CONTENTS 1. G-CSF Induced Pyoderma Gangrenosum.......................................................................3 2. Mastocytosis ...................................................................................................................8 3. Macroglobulinemia Cutis..............................................................................................12 4. Rosai-Dorfman..............................................................................................................15 5. Unknown.......................................................................................................................18 6. Cutaneous Involvement of Nodal B Cell Lymphoma...................................................19 7. Generalized Essential Telangiectasia............................................................................24 8. Habit-Tic Deformity Versus Median Nail Dystrophy ..................................................27 9. Diffuse Dermal Angiomatosis ......................................................................................30 10. PHACE Syndrome........................................................................................................32 11. Multiple Granular Cell Tumors ....................................................................................36 12. HPV Dysplasia of the Tongue ......................................................................................39
    [Show full text]
  • Skin Manifestations in COVID-19: Prevalence and Relationship with Disease Severity
    Journal of Clinical Medicine Article Skin Manifestations in COVID-19: Prevalence and Relationship with Disease Severity 1, 1, 2 1 Priscila Giavedoni y, Sebastián Podlipnik y , Juan M. Pericàs , Irene Fuertes de Vega , Adriana García-Herrera 3 , Llúcia Alós 3 , Cristina Carrera 1 , Cristina Andreu-Febrer 1, Judit Sanz-Beltran 1 , Constanza Riquelme-Mc Loughlin 1 , Josep Riera-Monroig 1 , Andrea Combalia 1, Xavier Bosch-Amate 1 , Daniel Morgado-Carrasco 1, Ramon Pigem 1, Agustí Toll-Abelló 1, Ignasi Martí-Martí 1, Daniel Rizo-Potau 1, Laura Serra-García 1 , Francesc Alamon-Reig 1 , Pilar Iranzo 1, Alex Almuedo-Riera 4 , Jose Muñoz 4, Susana Puig 1,5 and José M. Mascaró Jr. 1,* 1 Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona 08036, Spain; [email protected] (P.G.); [email protected] (S.P.); [email protected] (I.F.d.V.); [email protected] (C.C.); [email protected] (C.A.-F.); [email protected] (J.S.-B.); [email protected] (C.R.-M.L.); [email protected] (J.R.-M.); [email protected] (A.C.); [email protected] (X.B.-A.); [email protected] (D.M.-C.); [email protected] (R.P.); [email protected] (A.T.-A.); [email protected] (I.M.-M.); [email protected] (D.R.-P.); [email protected] (L.S.-G.); [email protected] (F.A.-R.); [email protected] (P.I.) 2 Infectious Diseases Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona 08036, Spain; [email protected] 3 Pathology Department, Hospital Clinic of Barcelona, University of Barcelona, Barcelona 08036, Spain; [email protected] (A.G.-H.); [email protected] (L.A.) 4 International Health Department ISGlobal, Hospital Clinic, University of Barcelona; Barcelona 08036, Spain; [email protected] (A.A.-R.); [email protected] (J.M.) 5 CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona 08036, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-93-2275586; Fax: +34-93-4514438/5424 These authors contributed equally to this work.
    [Show full text]
  • Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy
    International Journal of Molecular Sciences Review Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy Yasuteru Inoue 1,* , Yukio Ando 2, Yohei Misumi 1 and Mitsuharu Ueda 1 1 Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan; [email protected] (Y.M.); [email protected] (M.U.) 2 Department of Amyloidosis Research, Nagasaki International University, Sasebo 859-3298, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-96-373-5893; Fax: +81-96-373-5895 Abstract: Cerebral amyloid angiopathy (CAA) is characterized by accumulation of amyloid β (Aβ) in walls of leptomeningeal vessels and cortical capillaries in the brain. The loss of integrity of these vessels caused by cerebrovascular Aβ deposits results in fragile vessels and lobar intracere- bral hemorrhages. CAA also manifests with progressive cognitive impairment or transient focal neurological symptoms. Although development of therapeutics for CAA is urgently needed, the pathogenesis of CAA remains to be fully elucidated. In this review, we summarize the epidemiology, pathology, clinical and radiological features, and perspectives for future research directions in CAA therapeutics. Recent advances in mass spectrometric methodology combined with vascular isolation techniques have aided understanding of the cerebrovascular proteome. In this paper, we describe several potential key CAA-associated molecules that have been identified by proteomic analyses (apolipoprotein E, clusterin, SRPX1 (sushi repeat-containing protein X-linked 1), TIMP3 (tissue in- hibitor of metalloproteinases 3), and HTRA1 (HtrA serine peptidase 1)), and their pivotal roles in Citation: Inoue, Y.; Ando, Y.; Misumi, Aβ cytotoxicity, Aβ fibril formation, and vessel wall remodeling.
    [Show full text]
  • Thrombotic Microangiopathy As a Cause of Cardiovascular Toxicity from the BCR-ABL1 Tyrosine Kinase Inhibitor Ponatinib
    From www.bloodjournal.org by guest on April 19, 2019. For personal use only. Regular Article VASCULAR BIOLOGY Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib Yllka Latifi,1,* Federico Moccetti,1,* Melinda Wu,1,2 Aris Xie,1 William Packwood,1 Yue Qi,1 Koya Ozawa,1 Weihui Shentu,1 Eran Brown,1 Toshiaki Shirai,3 Owen J. McCarty,3 Zaverio Ruggeri,4 Javid Moslehi,5 Junmei Chen,6 Brian J. Druker,7 Jose A. Lopez,´ 6 and Jonathan R. Lindner1,8 1Knight Cardiovascular Institute, 2Doernbecher Children’s Hospital, and 3Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR; 4Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA; 5Cardiovascular Division, Vanderbilt University, Nashville, TN; 6Bloodworks NW, Seattle, WA; 7Knight Cancer Institute, Oregon Health & Science University, Portland, OR; and 8Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR KEY POINTS The third-generation tyrosine kinase inhibitor (TKI) ponatinib has been associated with high rates of acute ischemic events. The pathophysiology responsible for these events l Ponatinib therapy can result in VWF- is unknown. We hypothesized that ponatinib produces an endothelial angiopathy in- mediated platelet volving excessive endothelial-associated von Willebrand factor (VWF) and secondary adhesion to the platelet adhesion. In wild-type mice and ApoE2/2 mice on a Western diet, ultrasound microvascular molecular imaging of the thoracic aorta for VWF A1-domain and glycoprotein-Iba endothelium. was performed to quantify endothelial-associated VWF and platelet adhesion. Af- l Ponatinib-related ter treatment of wild-type mice for 7 days, aortic molecular signal for endothelial- microangiopathy can associated VWF and platelet adhesion were five- to sixfold higher in ponatinib vs sham reduce segmental P < 2/2 left ventricular therapy ( .001), whereas dasatinib had no effect.
    [Show full text]